AstraZeneca Acquires Icosavax

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.

Pfizer Acquires ReViral Ltd.

April 7, 2022

Biotechnology

Pfizer Inc. has completed its acquisition of ReViral Ltd., a clinical-stage biopharmaceutical company developing antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525 million including milestones. The deal brings ReViral's lead candidate sisunatovir and an RSV N-protein program into Pfizer's anti-infective pipeline to complement its RSV vaccine efforts and accelerate therapeutic development and commercialization.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.